Intercept Pharmaceuticals (ICPT) Reaches $115.91 After 9.00% Up Move; Glaxosmithkline Plc (GSK) Shorts Lowered By 19.47%

May 24, 2017 - By Migdalia James

The stock of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) is a huge mover today! About 128,763 shares traded. Intercept Pharmaceuticals Inc (NASDAQ:ICPT) has declined 14.52% since May 24, 2016 and is downtrending. It has underperformed by 31.22% the S&P500.The move comes after 9 months positive chart setup for the $2.88B company. It was reported on May, 24 by Barchart.com. We have $126.34 PT which if reached, will make NASDAQ:ICPT worth $259.20 million more.

Glaxosmithkline Plc (NYSE:GSK) had a decrease of 19.47% in short interest. GSK’s SI was 4.59 million shares in May as released by FINRA. Its down 19.47% from 5.70 million shares previously. With 3.08M avg volume, 2 days are for Glaxosmithkline Plc (NYSE:GSK)’s short sellers to cover GSK’s short positions. The SI to Glaxosmithkline Plc’s float is 0.19%. About 711,798 shares traded. GlaxoSmithKline plc (ADR) (NYSE:GSK) has risen 4.26% since May 24, 2016 and is uptrending. It has underperformed by 12.44% the S&P500.

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $2.88 billion. The Firm is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. It currently has negative earnings. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Investors sentiment decreased to 0.99 in Q4 2016. Its down 0.23, from 1.22 in 2016Q3. It turned negative, as 37 investors sold Intercept Pharmaceuticals Inc shares while 38 reduced holdings. 19 funds opened positions while 55 raised stakes. 20.29 million shares or 0.16% more from 20.26 million shares in 2016Q3 were reported. Balyasny Asset Mngmt Ltd Co stated it has 0.01% of its portfolio in Intercept Pharmaceuticals Inc (NASDAQ:ICPT). Altrinsic Global Limited Liability Corp has 0.76% invested in Intercept Pharmaceuticals Inc (NASDAQ:ICPT). 87,947 are owned by Citigroup. 110,715 are held by Price T Rowe Assocs Md. Bnp Paribas Arbitrage accumulated 4,016 shares. Td Asset Mngmt stated it has 4,000 shares. Qvt Limited Partnership has 62,306 shares for 0.21% of their portfolio. Carmignac Gestion reported 1.71% of its portfolio in Intercept Pharmaceuticals Inc (NASDAQ:ICPT). Axa holds 94,789 shares. Amalgamated National Bank stated it has 0.01% in Intercept Pharmaceuticals Inc (NASDAQ:ICPT). Deutsche Comml Bank Ag stated it has 181,983 shares. Emerald Advisers Pa accumulated 85,603 shares. Financial Bank Of America De owns 366,067 shares. Creative Planning reported 3,852 shares or 0% of all its holdings. Cap Ww Investors has 2.14M shares.

Among 17 analysts covering Intercept Pharmaceuticals (NASDAQ:ICPT), 9 have Buy rating, 4 Sell and 4 Hold. Therefore 53% are positive. Intercept Pharmaceuticals has $423 highest and $58 lowest target. $184.98’s average target is 59.59% above currents $115.91 stock price. Intercept Pharmaceuticals had 27 analyst reports since August 10, 2015 according to SRatingsIntel. Vetr upgraded Intercept Pharmaceuticals Inc (NASDAQ:ICPT) rating on Thursday, September 17. Vetr has “Strong-Buy” rating and $207.80 target. Barclays Capital maintained the stock with “Overweight” rating in Wednesday, February 24 report. The firm has “Equal-Weight” rating given on Friday, January 29 by Morgan Stanley. Goldman Sachs initiated the stock with “Neutral” rating in Wednesday, March 30 report. The firm has “Outperform” rating given on Friday, December 30 by Wedbush. The firm earned “Outperform” rating on Wednesday, June 1 by Wedbush. The firm earned “Market Outperform” rating on Tuesday, May 31 by JMP Securities. The firm has “Outperform” rating given on Wednesday, February 24 by Wedbush. Morgan Stanley downgraded the shares of ICPT in report on Friday, April 8 to “Underperform” rating. On Tuesday, May 31 the stock rating was maintained by Goldman Sachs with “Neutral”.